Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Tevogen Inc. Common Stock

TVGN

Tevogen Inc is a healthcare enterprise engaged in biotechnology, artificial intelligence and technology, and healthcare services. Its operations focus on the development of biotechnology products, AI- and technology-based healthcare solutions, and healthcare service initiatives.

Last trade $5.77
Day change -$0.455 (-7.32%)
Day range $5.64 – $6.20
Volume 1,421
Market cap $421M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$421.5M
Price / earnings
—
Price / book
-47.42×
Price / sales
—
EV / sales
—
EV / EBITDA
-20.44×

Profitability

Earnings per share
-$0.33
Return on assets
-472.48%
Return on equity
251.3%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.91×
Current ratio
0.33×
Quick ratio
0.33×
Cash ratio
0.18×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.63M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TVGN, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.38M$2.27M$2.5M$2.62M$2.74M$7.16M$6.53M$2.82M
Research and development$3.28M$3.13M$2.11M$3.11M$2.7M$3.2M$2.84M$3.26M
Total operating expenses$5.66M$5.4M$4.61M$5.73M$5.44M$10.36M$1.86M$6.09M
Operating income-$5.66M-$5.4M-$4.61M-$5.73M-$5.44M-$10.36M-$1.86M-$6.09M
Interest expense-$98.39K$0-$70.67K-$62.34K-$38.03K$0-$15.8K-$12.46K
Income before taxes-$5.76M-$5.45M-$4.68M-$5.73M-$5.5M-$10.37M-$9.44M-$5.88M
Income taxes$0$0$0$0$0$0$0$0
Net income-$5.76M-$5.45M-$4.68M-$5.73M-$5.5M-$10.37M-$9.44M-$5.88M
Net income attributable to common shareholders-$5.76M-$5.62M-$5.23M-$5.73M-$5.5M-$10.5M-$5.99M-$5.88M
EBITDA-$5.63M-$5.37M-$4.23M-$5.73M-$5.35M-$10.32M-$9.08M-$6.04M
Basic earnings per share-$1.52-$1.61-$1.84-$1.50-$1.71-$3.25-$2.40-$1.50
Diluted earnings per share-$1.52-$1.61-$1.84-$1.50-$1.71-$3.25-$2.50-$1.50

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced its 2026 Annual Meeting of Stockholders scheduled for August 24, 2026, to be held virtually. The company has set July 23, 2026 as the record date for stockholders and the deadline for submitting stockholder proposals and director nominations. Tevogen continues to focus on its three complementary initiatives: Tevogen Bio (biotechnology), Tevogen.AI (artificial intelligence and technology), and Tevogen Healthcare Services, aimed at improving affordability and accessibility of life-saving medicines.

Benzinga

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-binding Letter of Intent to evaluate acquiring a Management Services Organization (MSO). If completed, the transaction could expand Tevogen's healthcare infrastructure and support its evolution into a revenue-generating enterprise with combined annual revenue of approximately $100 million, alongside its biotechnology and AI technology arms.

GlobeNewswire Inc.

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen Bio Holdings Inc. announced capital discipline measures including its lead investor Dr. Manmohan Patel's commitment to maintain shareholdings, a pledge to limit share utilization to 1% of authorized shares over the next 12 months or until cash-flow positive, and evaluation of acquisitions that could generate over $50 million in combined annual revenue. The company is also exploring ways to better reflect the value of its assets and continues to evaluate a potential special cash dividend.

GlobeNewswire Inc.

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced progress on TVGN 489, its investigational T-cell therapy for Long COVID, following the appointment of a new leadership team on March 9, 2026. The company expanded HLA target coverage to reach 65% of the U.S. population and is evaluating the acquisition of Sciometrix's Clinicus platform for real-world patient monitoring. Proof-of-concept data showed 100% of treated high-risk patients did not develop Long COVID.

Benzinga

Tevogen Bio Explores Buyout To Boost Generics Platform

Tevogen Bio Holdings (NASDAQ:TVGN) announced a non-binding Letter of Intent to explore acquiring Apozeal Pharmaceutical Inc. to strengthen its generics platform and enhance pharmaceutical affordability. The stock surged to $10.8 before falling, and is now trading at a 52-week low of $6.56, down 15.41% on the day. The company also approved a 50-for-1 reverse stock split and is considering other life sciences transactions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 6, 20261-for-50reverse split